@article{a6068abd0d08493fbaec08fd45f01c9f,
title = "Reply to G Taubes, MI Friedman, and V Torres-Carot et al.",
author = "Hall, {Kevin D.} and Farooqi, {I. Sadaf} and Friedman, {Jeffery M.} and Samuel Klein and Loos, {Ruth J.F.} and Mangelsdorf, {David J.} and Stephen O{\textquoteright}Rahilly and Eric Ravussin and Redman, {Leanne M.} and Ryan, {Donna H.} and Speakman, {John R.} and Tobias, {Deirdre K.}",
note = "Funding Information: Supported by NIH grant 1ZIADK013037 (to KDH). KDH has participated in several debates with David S Ludwig on theories of obesity and has received funding from the Nutrition Science Initiative to test predictions of the CIM. JMF reports royalty payments for leptin for the treatment of lipodystrophy. SK serves as a scientific consultant for Altimmune, Janssen, and B2M and has a sponsored research agreement with Janssen. SOR receives remuneration for scientific advice from Pfizer, AstraZeneca, and ThirdRock Ventures. DHR reports personal fees from Altimmune, Amgen, Gila Therapeutics, Phenomix, Quintiles, Rhythm, YSOPIA, Zealand, Lilly, and Wondr Health, and Roman Health, and personal fees and nonfinancial support from Boeringer Ingelheim, Calibrate, Epitomee, IFA Celtic, Janssen, Novo Nordisk, real appeal (United Health Care), Sanofi, Scientific Intake, and Xeno Bioscience, outside the submitted work. All other authors report no conflicts of interest.",
year = "2022",
month = aug,
day = "1",
doi = "10.1093/ajcn/nqac163",
language = "English (US)",
volume = "116",
pages = "614--616",
journal = "American Journal of Clinical Nutrition",
issn = "0002-9165",
publisher = "American Society for Nutrition",
number = "2",
}